Phase 2 Pancreatic Cancer Trial, Recruiting NCT07595835 Sponsor: M.R. Meijerink Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT07595835
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with locally advanced pancreatic cancer that has grown into nearby blood vessels in a significant way (based on specific medical measurements — confirm with trial site)
  • Your cancer has not grown (has stayed stable or improved) after at least two months of chemotherapy treatment
  • You are able and willing to give your written and spoken agreement to take part
  • A specialist medical team has reviewed your case and agreed you are a suitable candidate for this type of treatment
  • You are in reasonably good general health, able to carry out daily activities with little or no restriction (rated 0–2 on the WHO scale — confirm with trial site)

Who may not be able to join:

  • Your cancer can be removed by surgery
  • You are already taking part in another trial testing a different type of tumour-destroying treatment (such as radiofrequency ablation or irreversible electroporation) for your pancreatic cancer
  • You have a known allergy or sensitivity to silicon or phosphorus
  • You have a blood clotting disorder that cannot be controlled with medication
  • You are unwilling or unable to stop taking blood-thinning medication for the procedure
  • You are pregnant
  • Your pancreatic cancer has spread to other parts of the body
  • You have had an epileptic seizure in the past six months
  • Your tumour is larger than 70 mm at its widest point, or the total tumour size exceeds a certain volume (confirm with trial site)
  • Scans show a large number of blood vessels surrounding your tumour that would make the treatment injection unsafe
  • Scans show swollen or enlarged veins (varices) near your tumour, or you are at significant risk of developing them
  • You have recently had a significant flare-up of pancreatitis (inflammation of the pancreas)
  • You have previously had radiotherapy treatment directed at your pancreas

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +31204444571

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
M.R. Meijerink
Registry
ClinicalTrials.gov
Start date
4 June 2023
Est. completion
1 June 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Safety defined as the rate of procedure- or device-related CTCAE grade ≥3 adverse events (AEs) within 90 days after implantion.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov